Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes

ABSTRACT: Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes

PROVIDER: PRJNA1079330 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28165400_1.fastq.gz	Fastqsanger.gz
	SRR28165400_2.fastq.gz	Fastqsanger.gz
	SRR28165500_1.fastq.gz	Fastqsanger.gz
	SRR28165500_2.fastq.gz	Fastqsanger.gz
	SRR28165401_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 384

Similar Datasets

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes [RNAseq]

Project description:Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes [RNAseq]

| PRJNA910114 | ENA

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes [array]

Project description:Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes [array]

| PRJNA1079332 | ENA

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes [array]

Project description:Lower-risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by early accumulation of somatic mutations in epigenetic factors and non-epigenetic factors that may produce convergent DNA methylation patterns driving specific gene expression profiles. The integration of genomic, epigenomic and transcriptomic profiling has the potential to spotlight distinct LR-MDS categories on the basis of pathophysiological mechanisms.

2025-01-29 | GSE256394 | GEO

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes [RNAseq]

2025-01-29 | GSE220518 | GEO

ZRSR2 mutant myelodysplastic syndromes

Project description:ZRSR2 mutant myelodysplastic syndromes

| PRJNA671387 | ENA

ZRSR2 mutant myelodysplastic syndromes

Project description:ZRSR2 mutant myelodysplastic syndromes

| PRJNA671388 | ENA

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes

Project description:This SuperSeries is composed of the SubSeries listed below.

2025-01-29 | GSE256396 | GEO

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes.

Project description:Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent DNA methylation patterns driving specific gene expression profiles. The integration of genomic, epigenomic, and transcriptomic profiling has the potential to spotlight distinct LR-MDS categories on the basis of pathophysiological mechanisms. We performed a comprehensive study of somatic mutations and DNA methylation in a large and clinically well-annotated cohort of treatment-naive patients with LR-MDS at diagnosis from the EUMDS registry (ClinicalTrials.gov.NCT00600860). Unsupervised clustering analyses identified six clusters based on genetic profiling that concentrate into four clusters on the basis of genome-wide methylation profiling with significant overlap between the two clustering modes. The four methylation clusters showed distinct clinical and genetic features and distinct methylation landscape. All clusters shared hypermethylated enhancers enriched in binding motifs for ETS and bZIP (C/EBP) transcription factor families, involved in the regulation of myeloid cell differentiation. By contrast, one cluster gathering patients with early leukemic evolution exhibited a specific pattern of hypermethylated promoters and, distinctly from other clusters, the upregulation of AP-1 complex members FOS/FOSL2 together with the absence of hypermethylation of their binding motif at target gene enhancers, which is of relevance for leukemic initiation. Among MDS patients with lower-risk IPSS-M, this cluster displayed a significantly inferior overall survival (p < 0.0001). Our study showed that genetic and DNA methylation features of LR-MDS at early stages may refine risk stratification, therefore offering the frame for a precocious therapeutic intervention.

| S-EPMC11754767 | biostudies-literature

Oxidative stress in myelodysplastic syndromes

Project description:Control of oxidative stress in the bone marrow (BM) is key for maintaining the balance between self-renewal, proliferation, and differentiation of hematopoietic cells. Breakdown of this regulation can lead to diseases characterized by BM failure such as the myelodysplastic syndromes (MDS). To better understand the role of oxidative stress in MDS development, we compared protein carbonylation as an oxidative stress marker in BM of patients with MDS and control subjects, and also patients with MDS under treatment with the iron chelator deferasirox.

2019-10-30 | PXD013609 | Pride

The National Myelodysplastic Syndromes (MDS) Study

Project description:The National Myelodysplastic Syndromes (MDS) Study

| PRJNA783118 | ENA